Shift work disorder affects roughly 27 percent of adult shift workers, according to the pooled estimate cited in the guideline, with a 95 percent confidence interval of 21 to 33 percent. Patients typically present with excessive sleepiness during their major wake period, sleep disturbance or insomnia during their attempted daytime sleep, or both. The underlying driver is misalignment between the endogenous circadian system, the internal clock that orchestrates sleepiness, alertness, hormone release and metabolism across roughly 24 hours, and the required shift work schedule, although the pathophysiology remains incompletely understood. Not every shift worker develops the disorder, and the circadian rhythms of the majority of shift workers never adapt to their schedules at all. That biological stubbornness shapes the entire guideline: because circadian adaptation is not a common or realistic treatment goal for most patients, the majority of recommendations focus on managing sleepiness and insomnia symptoms rather than retraining the clock.

The stakes extend far beyond feeling tired at work. Exposure to shift work increases risk for numerous poor health outcomes, including poor quality of life, unwanted weight gain, cardiometabolic disorders, neurological disorders, mood disorders, reproductive health challenges and malignancy. Yet the guideline is explicit that studies to date primarily examine symptom management, and the longer-term health impacts of interventions for shift work disorder were not evaluated in the research reviewed. The evidence base itself is a patchwork: it draws largely on laboratory studies of simulated shift work in healthy adults, real-life field studies of shift workers who were never formally diagnosed with the disorder, and only a small number of randomized multicenter clinical trials in diagnosed patients. The task force also screened for clinically meaningful thresholds on critical outcomes such as excessive sleepiness, accident risk, sleep quality and cognitive performance, and interventions missing the mark on those critical outcomes were judged by important outcomes including circadian alignment, quality of life and mental health.

The strongest evidence in the entire guideline belongs to the wake-promoting medications armodafinil and modafinil, taken 30 to 60 minutes before the night shift. These are the only FDA-approved medications for treating excessive sleepiness in patients with shift work disorder, and the recommendation carries moderate certainty of evidence, the highest grade assigned. Across five randomized controlled trials for each drug, pooled estimates showed clinically meaningful decreases in excessive sleepiness and accident risk, measured through increased sleep latency on the multiple sleep latency test, reduced self-reported sleepiness on the Karolinska Sleepiness Scale, and fewer lapses of attention on the psychomotor vigilance task. Armodafinil appears to have a longer duration of effect than modafinil with respect to objectively measured sleepiness. The task force judged undesirable effects small but real: headache and nausea were the most common reasons for withdrawal from studies, and rare but serious adverse events have included life-threatening rash, multi-organ hypersensitivity reactions and suicidal ideation in a patient with a history of depression. Reports of abuse and dependence exist, safety in pregnancy is not established, and these medications can reduce the effectiveness of hormonal birth control, particularly oral contraceptives and implants.

For patients and clinicians seeking drug-free options, the guideline suggests several conditional interventions with very low certainty of evidence. Bright light exposure during the night shift, drawn from eighteen randomized trials testing intensities ranging from 361 to 10,000 lux over durations from 20 minutes to 9 hours, showed potentially meaningful reductions in sleepiness and improvements in vigilance, likely acting through the alerting effects of light on the brain, reductions in melatonin levels and increases in body temperature at night. Caffeine taken before or during the early night shift similarly reduced objective and subjective sleepiness, but the guideline warns that caffeine within six hours of sleep reduces sleep duration and quality, appears more disruptive to daytime than nighttime sleep, and that susceptibility varies with adenosine receptor gene polymorphisms. A nap before the night shift improved alertness in the small number of trials reviewed, yet the task force flagged sleep inertia, the groggy state after waking that can temporarily impair cognition and increase accident risk, advising more than 20 minutes of recovery before driving or other safety-sensitive behaviors. Perhaps most surprising, the guideline suggests not eating or eating only a snack rather than a full meal during the night shift, based on four trials showing improvements in sleepiness, driving-simulator accident risk and vigilance, a strategy grounded in the recognition that most shift workers never fully adapt and their metabolic processes remain most active during the biological daytime.

On the insomnia side, the guideline suggests melatonin after the night shift, melatonin for night sleep when transitioning away from shift work, and melatonin before a daytime nap prior to the first night shift, all conditional. Doses in the reviewed studies ranged from 0.1 to 40 milligrams, reflecting melatonin’s dual role as both a sleep-promoting agent and a circadian phase-resetting signal depending on dose and timing. The guideline also cautions that over-the-counter melatonin supplements vary wildly, with one study finding actual melatonin content ranging from 83 percent below to 478 percent above the labeled amount. Ramelteon, an 8-milligram melatonin receptor agonist, and suvorexant, a dual orexin receptor antagonist tested at 10 and 20 milligrams, earned conditional suggestions with low certainty, showing clinically meaningful increases in self-reported and objectively measured daytime sleep duration. Suvorexant’s stronger 20-milligram effect came with known side effects including drowsiness, dizziness, headache, unusual dreams and dry mouth, and a 30-milligram dose has not been approved due to increased suicidal ideation. Cognitive behavioral therapy for insomnia, the gold-standard treatment for chronic insomnia, also earned a conditional suggestion, though the guideline notes that all reviewed studies used protocols modified for shift workers, such as tailored sleep hygiene scheduling sleep, meals and exercise around shifts, and that access is limited by a shortage of trained providers.

One recommendation points in the opposite direction. The task force suggests against triazolam and other benzodiazepines for daytime sleep disturbance, despite four randomized trials showing the drug meaningfully increased sleep duration and reduced sleepiness. The reasoning is a classic risk-benefit calculation: chronic benzodiazepine use carries concerns about falls, abuse, dependence and withdrawal symptoms, and the task force judged the magnitude of these undesirable effects moderate, concluding that potential harm outweighed the demonstrated benefits. Clinical practice has already shifted away from long-term benzodiazepine use, and the task force concluded the drugs would probably not be acceptable to key interest holders. The guideline adds a practical warning that applies to all sleep-promoting medications: many shift workers attempting to sleep during the day still hold daytime responsibilities such as childcare, so they may lack a fully protected eight-hour sleep window, and the risks of residual sedation must be weighed against the benefits of improved daytime sleep.

For the minority of patients seeking true circadian adaptation to stable night shifts, the guideline suggests bright light at night, the combination of bright light with fixed daytime sleep timing, and the three-part combination adding reduced-light-transmittance glasses worn during the morning commute home. The evidence, from studies in which individuals achieved partial circadian adaptation, showed meaningful improvements in accident risk and sleep duration. But the guideline is blunt about who benefits: for individuals working rotating or frequently changing shifts, circadian adaptation is not a realistic treatment goal and they would not be expected to benefit. Full adaptation carries its own paradox, since workers would then be circadian misaligned on days off when they return to nighttime sleep, making partial alignment a reasonable compromise shown to improve performance, alertness and mood. The glasses recommendation comes with a driving-safety caveat, because dimming morning light may decrease alertness behind the wheel.

The guideline also declines to favor 8-hour over 12-hour night shifts, finding no differences in sleepiness, sleep quality or cognitive performance across five observational studies, though it did not examine shifts exceeding 12 hours or weekly totals beyond the 36 to 52 hours represented in the data. Interventions including light-filtering glasses, planned work schedules, split sleep and planned naps during shifts received no recommendations because the evidence was insufficient and inconclusive, a distinction the task force stresses does not mean such interventions fail, only that evidence was lacking to guide decision-making. Looking forward, the task force identifies a glaring research gap: very few clinical trials enrolled individuals with a formal diagnosis of shift work disorder, long-term effects of chronic armodafinil and modafinil use remain unstudied, and the effects of these medications on actual accident rates and on long-term morbidity such as cardiometabolic disease and malignancy have never been examined. A large segment of the workforce, early morning shift workers, meets the criteria of working during normal sleep hours yet remains largely absent from research. Until those studies arrive, the guideline’s message is one of individualized pragmatism: treatment must be crafted around each patient’s shift schedule, rotation, commute, family demands and symptoms, with clinicians using these conditional suggestions as building blocks rather than blueprints.

Subject of Research: Clinical practice guideline for the management of shift work disorder

Article Title: Management of shift work disorder: an American Academy of Sleep Medicine clinical practice guideline

Article References: Wright, K. P., Jr., Abbott, S. M., Ashbrook, L., Drake, C. L., Flynn-Evans, E., Framnes-DeBoer, S., Kazmi, U., Keeler, K., McCall, C., Morgan, R., Shaffer-Hodgeman, T., & Trotti, L. M. (2026). Management of shift work disorder: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 22(1), Article 202. https://doi.org/10.1007/s44470-026-00084-w

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00084-w

Keywords: Management, shift, work, disorder, American, Academy, Sleep, Medicine, clinical, practice, guideline, scientific research